Imaging Non-motor Symptoms of Parkinson's Disease by Novel 18F-DTBZ and Florbetapir F-18 PET

Model scores of the 29,894 trials active now.

Model score 9% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (453 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: subjectsor femaleclinically significantmildmale
  Phrases that lowered it: patients whobrainiiiiistudy entry
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Sponsor's past termination rate: 2.7% (lowers risk) · Sponsor's track record
• Minimum age: 20 (lowers risk) · Who can join
• Phase: 2 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 52 (lowers risk) · Sponsor's track record
• Responsible party: principal investigator (lowers risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: single group (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Disease area, neurology: Yes (raises risk) · Disease area
• Maximum age: 80 (lowers risk) · Who can join
• Primary purpose: diagnostic (lowers risk) · Design
• Collaborators: 1 (raises risk) · Design
• Sponsor's past trials: 37 (lowers risk) · Sponsor's track record
• Blinding: none (raises risk) · Design
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Number of arms: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Developing a Novel Imaging Biomarker in the Differential Diagnosis of Parkinson's Disease and Parkinsonism NCT02059733 · started 2013 · scored riskier than 19% of active trials completed
• Investigating the Microstructural and Functional Alterations of Brain in Parkinson's Disease Patients NCT02599753 · started 2015 · scored riskier than 10% of active trials completed
• The Differential Diagnosis of Parkinson's Disease and Parkinsonism by Positron-emission Tomography NCT01824056 · started 2010 · scored riskier than 21% of active trials completed
• Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients NCT00857532 · started 2009 · scored riskier than 31% of active trials completed
• Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss NCT03587649 · started 2018 · scored riskier than 25% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.